About this Journal Submit a Manuscript Table of Contents
ISRN AIDS
Volume 2013 (2013), Article ID 471363, 22 pages
http://dx.doi.org/10.1155/2013/471363
Review Article

New Insights into HIV/AIDS-Associated Cryptococcosis

Department of Biomedical and Clinical Sciences Lvigi Sacco, Università degli Studi di Milano, Via GB Grassi 74, 20157 Milano, Italy

Received 13 December 2012; Accepted 10 January 2013

Academic Editors: C. A. Hughes and B. Joos

Copyright © 2013 Spinello Antinori. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. J. Park, K. A. Wannemuehler, B. J. Marston, N. Govender, P. G. Pappas, and T. M. Chiller, “Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS,” AIDS, vol. 23, no. 4, pp. 525–530, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. E. W. Bratton, N. El Husseini, C. A. Chastan, et al., “Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant,” PLoS One, vol. 7, Article ID e43582, 2012.
  3. F. Sanfelice, “Contributo alla morfologia e biologia dei blastomiceti che si sviluppano nei succhi di alcuni frutti,” Annali di Igiene, vol. 5, pp. 232–262, 1894.
  4. O. Busse, “Uber parasitare zelleinschlusse und threzuchtung,” Zbl Bakt I Abt, vol. 16, pp. 175–180, 1894.
  5. A. Buschke, “Ueber eine durch coccidien hervegerufene krankheit des menschen,” Deutsche Medizinische Wochenschrift, vol. 21, no. 1, pp. 14–15, 1895. View at Publisher · View at Google Scholar
  6. J. A. Barnett, “A history of research on yeasts 14:1 medical yeasts—part 2: Cryptococcus neoformans,” Yeast, vol. 27, no. 11, pp. 875–904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. S. L. Chuck and M. A. Sande, “Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome,” The New England Journal of Medicine, vol. 321, no. 12, pp. 794–799, 1989. View at Scopus
  8. F. Dromer, S. Mathoulin, B. Dupont, and A. Laporte, “Epidemiology of cryptococcosis in France: a 9-year survey (1985–1993). French Cryptococcosis Study Group,” Clinical Infectious Diseases, vol. 23, no. 1, pp. 82–90, 1996. View at Scopus
  9. B. Speed and D. Dunt, “Clinical and host differences between infections with the two varieties of Cryptococcus neoformans,” Clinical Infectious Diseases, vol. 21, no. 1, pp. 28–34, 1995. View at Scopus
  10. S. A. Mirza, M. Phelan, D. Rimland et al., “The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992–2000,” Clinical Infectious Diseases, vol. 36, no. 6, pp. 789–794, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. L. J. R. van Elden, A. M. E. Walenkamp, M. M. Lipovsky et al., “Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy,” AIDS, vol. 14, no. 17, pp. 2787–2788, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Dromer, S. Mathoulin-Pélissier, A. Fontanet, O. Ronin, B. Dupont, and O. Lortholary, “Epidemiology of HIV-associated cryptococcosis in France (1985–2001): comparison of the pre- and post-HAART eras,” AIDS, vol. 18, no. 3, pp. 555–562, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Antinori, A. L. Ridolfo, M. Fasan et al., “AIDS-associated cryptococcosis: a comparison of epidemiology, clinical features and outcome in the pre- and post-HAART eras. Experience of a single centre in Italy,” HIV Medicine, vol. 10, no. 1, pp. 6–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Kambugu, D. B. Meya, J. Rhein et al., “Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy,” Clinical Infectious Diseases, vol. 46, no. 11, pp. 1694–1701, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. N. Jarvis, A. Boulle, A. Loyse et al., “High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out,” AIDS, vol. 23, no. 9, pp. 1182–1183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. J. R. Harris, M. D. Lindsley, S. Henchaichon, et al., “High prevalence of cryptococcal infection among HIV-infected patients hospitalized with pneumonia in Thailand,” Clinical Infectious Diseases, vol. 54, no. 5, pp. e43–e50, 2012. View at Publisher · View at Google Scholar
  17. K. J. Kwon-Chung, T. Boekhout, J. W. Fell, and M. Diaz, “Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae),” Taxon, vol. 51, no. 4, pp. 804–806, 2002. View at Scopus
  18. K. J. Kwon-Chung and A. Varma, “Do major species concepts support one, two or more species within Cryptococcus neoformans?” FEMS Yeast Research, vol. 6, no. 4, pp. 574–587, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Lin and J. Heitman, “The biology of the Cryptococcus neoformans species complex,” Annual Review of Microbiology, vol. 60, pp. 69–105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Dromer, S. Mathouline-Pélissier, O. Launay, O. Lotholary, and The French Cryptococcosis Study Group, “Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study,” PLoS Medicine, vol. 4, no. 2, article e21, 2007. View at Publisher · View at Google Scholar
  21. D. H. Mitchell, T. C. Sorrell, A. M. Allworth et al., “Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome,” Clinical Infectious Diseases, vol. 20, no. 3, pp. 611–616, 1995. View at Scopus
  22. S. C. Chen, M. A. Slavin, C. H. Heath, et al., “Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death,” Clinical Infectious Diseases, vol. 55, no. 6, pp. 789–798, 2012. View at Publisher · View at Google Scholar
  23. T. Boekhout, B. Theelen, M. Diaz et al., “Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans,” Microbiology, vol. 147, no. 4, pp. 891–907, 2001. View at Scopus
  24. T. Khawcharoenporn, A. Apisarnthanarak, and L. M. Mundy, “Non-neoformans cryptococcal infections: a systematic review,” Infection, vol. 35, no. 2, pp. 51–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. M. E. Brandt, L. C. Hutwagner, L. A. Klug et al., “Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States,” Journal of Clinical Microbiology, vol. 34, no. 4, pp. 912–917, 1996. View at Scopus
  26. J. N. Steenbergen and A. Casadevall, “Prevalence of Cryptococcus neoformans var. neoformans (serotype D) and Cryptococcus neoformans var. grubii (serotype A) isolates in New York City,” Journal of Clinical Microbiology, vol. 38, no. 5, pp. 1974–1976, 2000. View at Scopus
  27. S. Chen, T. Sorrell, G. Nimmo et al., “Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand,” Clinical Infectious Diseases, vol. 31, no. 2, pp. 499–508, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. N. French, K. Gray, C. Watera et al., “Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults,” AIDS, vol. 16, no. 7, pp. 1031–1038, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. M. M. Nishikawa, M. S. Lazera, G. G. Barbosa et al., “Serotyping of 467 Cryptococcus neoformans isolates from clinical and environmental sources in Brazil: analysis of host and regional patterns,” Journal of Clinical Microbiology, vol. 41, no. 1, pp. 73–77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Meyer, A. Castaneda, S. Jackson, M. Huynh, E. Castaneda, and The IberoAmerican Cryptococcal Study group, “Molecular typing of IberoAmerican Cryptococcus neoformans isolates,” Emerging Infectious Diseases, vol. 9, no. 2, pp. 189–195, 2003. View at Publisher · View at Google Scholar
  31. A. P. Litvintseva, R. Thakur, L. B. Reller, and T. G. Mitchell, “Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in sub-Saharan Africa,” Journal of Infectious Diseases, vol. 192, no. 5, pp. 888–892, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Chaturvedi, M. Dyavaiah, R. A. Larsen, and V. Chaturvedi, “Cryptococcus gattii in AIDS patients, southern California,” Emerging Infectious Diseases, vol. 11, no. 11, pp. 1686–1692, 2005. View at Scopus
  33. M. A. Viviani, M. Cogliati, M. C. Esposto et al., “Molecular analysis of 311 Cryptococcus neoformans isolates from a 30-month ECMM survey of cryptococcosis in Europe,” FEMS Yeast Research, vol. 6, no. 4, pp. 614–619, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Lizarazo, M. Linares, C. de Bedout, A. Rastrepo, C. I. Agudelo, and Castaneda C y Grupo Colombiano para el Studio de la Criptococosis, “Estudio clínico y epidemiológico de la criptococosis en Colombia: resultados de nueve años de la encuesta nacional, 1997–2005,” Biomedica, vol. 27, no. 1, pp. 94–109, 2007.
  35. M. Capoor, D. Nair, M. Deb, B. Gupta, and P. Aggarwal, “Clinical and mycological profile of cryptococcosis in a tertiary care hospital,” Indian Journal of Medical Microbiology, vol. 25, no. 4, pp. 401–404, 2007. View at Scopus
  36. J. Chen, A. Varma, M. R. Diaz, A. P. Litvintseva, K. K. Wollenberg, and K. J. Kwon-Chung, “Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China,” Emerging Infectious Diseases, vol. 14, no. 5, pp. 755–762, 2008. View at Scopus
  37. M. R. Capoor, P. Mandal, M. Deb, P. Aggarwal, and U. Banerjee, “Current scenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for reappraisal,” Mycoses, vol. 51, no. 3, pp. 258–265, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. K. J. Kwon-Chung and J. E. Bennett, “Epidemiologic differences between the two varieties of Cryptococcus neoformans,” American Journal of Epidemiology, vol. 120, no. 1, pp. 123–130, 1984. View at Scopus
  39. D. H. Ellis, “Cryptococcus neoformans var. gattii in Australia,” Journal of Clinical Microbiology, vol. 25, no. 2, pp. 430–431, 1987. View at Scopus
  40. D. H. Ellis and T. J. Pfeiffer, “Natural habitat of Cryptococcus neoformans var. gattii,” Journal of Clinical Microbiology, vol. 28, no. 7, pp. 1642–1644, 1990. View at Scopus
  41. S. E. Kidd, F. Hagen, R. L. Tscharke et al., “A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada),” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 49, pp. 17258–17263, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Galanis and L. MacDougall, “Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999–2007,” Emerging Infectious Diseases, vol. 16, no. 2, pp. 251–257, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. E. J. Byrnes III, R. J. Bildfell, S. A. Frank, T. G. Mitchell, K. A. Marr, and J. Heitman, “Molecular evidence that the range of the Vancouver island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States,” Journal of Infectious Diseases, vol. 199, no. 7, pp. 1081–1086, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Chowdhary, H. S. Randahawa, T. Boekhout, F. Hagen, C. H. Klaassen, and J. F. Meis, “Temperate climate niche for Cryptococcus gattii in Northern Europe,” Emerging Infectious Diseases, vol. 18, no. 1, pp. 172–174, 2012. View at Publisher · View at Google Scholar
  45. K. Okamoto, S. Hatakeyama, S. Itoyama et al., “Cryptococcus gattii genotype VGIIa infection in man, Japan, 2007,” Emerging Infectious Diseases, vol. 16, no. 7, pp. 1155–1157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. S. E. Kidd, Y. Chow, S. Mak et al., “Characterization of environmental sources of the human and animal pathogen Cryptococcus gattii in British Columbia, Canada, and the Pacific Northwest of the United States,” Applied and Environmental Microbiology, vol. 73, no. 5, pp. 1433–1443, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. D. J. Springer and V. Chaturvedi, “Projecting global occurrence of Cryptococcus gattii,” Emerging Infectious Diseases, vol. 16, no. 1, pp. 14–20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. M. A. Viviani, S. Antinori, M. Cogliati et al., “European Confederation of Medical Mycology (ECMM) prospective survey of cryptococcosis: report from Italy,” Medical Mycology, vol. 40, no. 5, pp. 507–517, 2002. View at Scopus
  49. F. R. Knight, D. W. Mackenzie, B. G. Evans, K. Porter, N. J. Barrett, and G. C. White, “Increasing incidence of cryptococcosis in the United Kingdom,” Journal of Infection, vol. 27, no. 2, pp. 185–191, 1993. View at Scopus
  50. R. A. Hajjeh, M. E. Brandt, and R. W. Pinner, “Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery,” Epidemiologic Reviews, vol. 17, no. 2, pp. 303–320, 1995. View at Scopus
  51. L. Kaufman and S. Blumer, “Cryptococcosis: the awakening giant,” in Proceedings of the 4th International Conference on the Mycoses, pp. 176–182, Washington, DC, USA, 1978.
  52. C. D. Holtzer, M. A. Jacobson, W. K. Hadley et al., “Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994–1997,” AIDS, vol. 12, no. 14, pp. 1931–1933, 1998. View at Scopus
  53. J. F. Molez, “The historical question of acquired immunodeficiency syndrome in the 1960s in the Congo River basin area in relation to cryptococcal meningitis,” American Journal of Tropical Medicine and Hygiene, vol. 58, no. 3, pp. 273–276, 1998. View at Scopus
  54. M. Scarborough, S. B. Gordon, C. J. M. Whitty et al., “Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa,” The New England Journal of Medicine, vol. 357, no. 24, pp. 2441–2450, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. R. S. Heyderman, I. T. Gangaidzo, J. G. Hakim et al., “Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe,” Clinical Infectious Diseases, vol. 26, no. 2, pp. 284–289, 1998. View at Scopus
  56. J. G. Hakim, I. T. Gangaidzo, R. S. Heyderman et al., “Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients,” AIDS, vol. 14, no. 10, pp. 1401–1407, 2000. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Békondi, C. Bernede, N. Passone et al., “Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus,” International Journal of Infectious Diseases, vol. 10, no. 5, pp. 387–395, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. J. N. Jarvis, A. Boulle, A. Loyse et al., “High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out,” AIDS, vol. 23, no. 9, pp. 1182–1183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Bamba, O. Lortholary, A. Sawadogo, A. Millogo, R. T. Guiguemdé, and S. Bretagne, “Decreasing incidence of cryptococcal meningitis in West Africa in the era of highly active antiretroviral therapy,” AIDS, vol. 26, no. 8, pp. 1039–1041, 2012. View at Publisher · View at Google Scholar
  60. S. Sukroongreung, K. Kitiniyom, C. Nilakul, and S. Tantimavanich, “Pathogenicity of basidiospores of Filobasidiella neoformans var. neoformans,” Medical Mycology, vol. 36, no. 6, pp. 419–424, 1998. View at Scopus
  61. A. Idnurm, Y. S. Bahn, K. Nielsen, X. Lin, J. A. Fraser, and J. Heitman, “Deciphering the model pathogenic fungus Cryptococcus neoformans,” Nature Reviews Microbiology, vol. 3, no. 10, pp. 753–764, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. S. H. M. Chen, M. F. Stins, S. H. Huang et al., “Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells,” Journal of Medical Microbiology, vol. 52, no. 11, pp. 961–970, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. C. Chang, M. F. Stins, M. J. McCaffery, et al., “Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier,” Infection and Immunity, vol. 72, pp. 4985–4995, 2004. View at Publisher · View at Google Scholar
  64. M. Alvarez and A. Casadevall, “Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages,” Current Biology, vol. 16, no. 21, pp. 2161–2165, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Charlier, K. Nielsen, S. Daou, M. Brigitte, F. Chretien, and F. Dromer, “Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans,” Infection and Immunity, vol. 77, no. 1, pp. 120–127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Visnegarwala, E. A. Graviss, C. E. Lacke et al., “Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors,” Clinical Infectious Diseases, vol. 27, no. 5, pp. 1231–1237, 1998. View at Scopus
  67. J. A. Driver, C. A. Saunders, B. Heinze-Lacey, and A. M. Sugar, “Cryptococcal pneumonia in AIDS: is cryptococcal meningitis preceded by clinically recognizable pneumonia?” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 9, no. 2, pp. 168–171, 1995. View at Scopus
  68. S. Deok-Jong Yoo, W. Worodria, J. L. Davis et al., “The prevalence and clinical course of HIV-associated pulmonary cryptococcosis in Uganda,” Journal of Acquired Immune Deficiency Syndromes, vol. 54, no. 3, pp. 269–274, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. M. L. Wong, P. Back, G. Candy, G. Nelson, and J. Murray, “Cryptococcal pneumonia in African miners at autopsy,” International Journal of Tuberculosis and Lung Disease, vol. 11, no. 5, pp. 528–533, 2007. View at Scopus
  70. J. R. Harris, M. D. Lindsley, S. Henchaichton, et al., “High prevalence of cryptococcal infection among HIV-infected patients hospitalized with pneumonia in Thailand,” Clinical Infectious Diseases, vol. 54, pp. e43–e50, 2012. View at Publisher · View at Google Scholar
  71. K. Angstwurm, W. Sokolowska-Koehler, C. Stadelmann, E. Schielke, and J. R. Weber, “Fulminant cryptococcal meningitis as presenting feature in a patient with AIDS,” European Journal of Neurology, vol. 11, no. 5, pp. 353–354, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Zuger, E. Louie, R. S. Holzman, M. S. Simberkoff, and J. J. Rahal, “Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment,” Annals of Internal Medicine, vol. 104, no. 2, pp. 234–240, 1986. View at Scopus
  73. R. A. Clark, D. Greer, W. Atkinson, G. T. Valainis, and N. Hyslop, “Spectrum of Cryptococcus neoformans infection in 68 patients infected with human immunodeficiency virus,” Reviews of Infectious Diseases, vol. 12, no. 5, pp. 768–777, 1990. View at Scopus
  74. M. S. Saag, W. G. Powderly, G. A. Cloud et al., “Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis,” The New England Journal of Medicine, vol. 326, no. 2, pp. 83–89, 1992. View at Scopus
  75. C. Darras-Joly, S. Chevret, M. Wolff et al., “Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus,” Clinical Infectious Diseases, vol. 23, no. 2, pp. 369–376, 1996. View at Scopus
  76. C. M. van Der Horst, M. S. Saag, G. A. Cloud, et al., “Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome,” The New England Journal of Medicine, vol. 337, pp. 15–21, 1997. View at Publisher · View at Google Scholar
  77. S. Antinori, L. Galimberti, C. Magni et al., “Cryptococcus neoformans infection in a cohort of Italian AIDS patients: natural history, early prognostic parameters, and autopsy findings,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 20, no. 10, pp. 711–717, 2001. View at Publisher · View at Google Scholar · View at Scopus
  78. U. Jongwutiwes, S. Sungkanuparph, and S. Kiertiburanakul, “Comparison of clinical features and survival between cryptococcosis in human immunodeficiency virus (HIV)-positive and HIV-negative patients,” Japanese Journal of Infectious Diseases, vol. 61, no. 2, pp. 111–115, 2008. View at Scopus
  79. M. Hong Nguyen, S. Husain, C. J. Clancy et al., “Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study,” Journal of Infection, vol. 61, no. 5, pp. 419–426, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Y. S. Moosa and Y. M. Coovadia, “Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients,” Clinical Infectious Diseases, vol. 24, no. 2, pp. 131–134, 1997. View at Scopus
  81. J. Bogaerts, D. Rouvroy, H. Taelman et al., “AIDS-associated cryptococcal meningitis in Rwanda (1983–1992): epidemiologic and diagnostic features,” Journal of Infection, vol. 39, no. 1, pp. 32–37, 1999. View at Publisher · View at Google Scholar · View at Scopus
  82. P. Mwaba, J. Mwansa, C. Chintu et al., “Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions,” Postgraduate Medical Journal, vol. 77, no. 914, pp. 769–773, 2001. View at Publisher · View at Google Scholar · View at Scopus
  83. K. M. McCarthy, J. Morgan, K. A. Wannemuehler et al., “Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence,” AIDS, vol. 20, no. 17, pp. 2199–2206, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. J. D. Trachtenberg, A. D. Kambugu, M. McKellar et al., “The medical management of central nervous system infections in Uganda and the potential impact of an algorithm-based approach to improve outcomes,” International Journal of Infectious Diseases, vol. 11, no. 6, pp. 524–530, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. C. F. Schaars, G. A. Meintjes, C. Morroni, F. A. Post, and G. Maartens, “Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole,” BMC Infectious Diseases, vol. 6, article 118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. R. Rozenbaum and A. J. R. Goncalves, “Clinical epidemiological study of 171 cases of cryptococcosis,” Clinical Infectious Diseases, vol. 18, no. 3, pp. 369–380, 1994. View at Scopus
  87. C. H. Lu, W. N. Chang, H. W. Chang, and Y. C. Chuang, “The prognostic factors of cryptococcal meningitis in HIV-negative patients,” Journal of Hospital Infection, vol. 42, no. 4, pp. 313–320, 1999. View at Publisher · View at Google Scholar · View at Scopus
  88. C. C. Shih, Y. C. Chen, S. C. Chang, K. T. Luh, and W. C. Hsieh, “Cryptococcal meningitis in non-HIV-infected patients,” QJM, vol. 93, no. 4, pp. 245–251, 2000. View at Scopus
  89. P. G. Pappas, J. R. Perfect, G. A. Cloud et al., “Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy,” Clinical Infectious Diseases, vol. 33, no. 5, pp. 690–699, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Kiertiburanakul, S. Wirojtananugoon, R. Pracharktam, and S. Sungkanuparph, “Cryptococcosis in human immunodeficiency virus-negative patients,” International Journal of Infectious Diseases, vol. 10, no. 1, pp. 72–78, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. D. W. Denning, R. W. Armstrong, M. Fishman, and D. A. Stevens, “Endophthalmitis in a patient with disseminated cryptococcosis and AIDS who was treated with itraconazole,” Reviews of Infectious Diseases, vol. 13, no. 6, pp. 1126–1130, 1991. View at Scopus
  92. J. R. C. Crump, S. G. Elner, V. M. Elner, and C. A. Kauffman, “Cryptococcal endophthalmitis: case report and review,” Clinical Infectious Diseases, vol. 14, no. 5, pp. 1069–1073, 1992. View at Scopus
  93. R. R. Battu, J. Biswas, N. Jayakumar, H. N. Madhavan, N. Kumarsamy, and S. Solomon, “Papilloedema with peripapillary retinal haemorrhages in an acquired immunodeficiency syndrome (AIDS) patient with cryptococcal meningitis,” Indian Journal of Ophthalmology, vol. 48, no. 1, pp. 47–49, 2000. View at Scopus
  94. J. Duggan and H. M. Walls, “Ocular complications of cryptococcal meningitis in patients with HIV: report of two cases and review of the literature,” Journal of the International Association of Physicians in AIDS Care, vol. 11, pp. 283–288, 2012. View at Publisher · View at Google Scholar
  95. S. R. D. Johnston, E. L. Corbett, O. Foster, S. Ash, and J. Cohen, “Raised intracranial pressure and visual complications in AIDS patients with cryptococcal meningitis,” Journal of Infection, vol. 24, no. 2, pp. 185–189, 1992. View at Scopus
  96. A. M. Tortorano, M. A. Viviani, A. L. Rigoni, M. Cogliati, A. Roverselli, and A. Pagano, “Prevalence of serotype D in Cryptococcus neoformans isolates from HIV positive and HIV negative patients in Italy,” Mycoses, vol. 40, no. 7-8, pp. 297–302, 1997. View at Scopus
  97. F. Dromer, S. Mathoulin, B. Dupont, L. Letenneur, and O. Ronin, “Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. French Cryptococcosis Study Group,” Clinical Infectious Diseases, vol. 23, no. 1, pp. 91–96, 1996. View at Scopus
  98. L. R. Martinez, J. Garcia-Rivera, and A. Casadevall, “Cryptococcus neoformans var. neoformans (serotype D) strains are more susceptible to heat than C. neoformans var. grubii (serotype A) strains,” Journal of Clinical Microbiology, vol. 39, no. 9, pp. 3365–3367, 2001. View at Publisher · View at Google Scholar · View at Scopus
  99. C. E. Gonzalez, D. Shetty, L. L. Lewis, B. U. Mueller, P. A. Pizzo, and T. J. Walsh, “Cryptococcosis in human immunodeficiency virus-infected children,” Pediatric Infectious Disease Journal, vol. 15, no. 9, pp. 796–800, 1996. View at Publisher · View at Google Scholar · View at Scopus
  100. J. Abadi, S. Nachman, A. B. Kressel, and L. A. Pirofski, “Cryptococcosis in children with AIDS,” Clinical Infectious Diseases, vol. 28, no. 2, pp. 309–313, 1999. View at Scopus
  101. T. Gumbo, G. Kadzirange, J. Mielke, I. T. Gangaidzo, and J. G. Hakim, “Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome,” Pediatric Infectious Disease Journal, vol. 21, no. 1, pp. 54–56, 2002. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Likasitwattanakul, B. Poneprasert, and V. Sirisanthana, “Cryptococcosis in HIV-infected children,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 35, no. 4, pp. 935–939, 2004. View at Scopus
  103. S. T. Meiring, V. C. Quan, C. Cohen, et al., “A comparison of paediatric- and adult-onset cryptococcosis detected through population-based surveillance in South Africa, 2005–2007,” AIDS, vol. 26, pp. 2307–2314, 2012.
  104. N. S. Joshi, B. T. Fisher, P. A. Prasad, and T. E. Zaoutis, “Epidemiology of cryptococcal infection in hospitalized children,” Pediatric Infectious Disease Journal, vol. 29, no. 12, pp. e91–e95, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. C. B. Severo, M. O. Xavier, A. F. Gazzoni, and L. C. Severo, “Cryptococcosis in children,” Paediatric Respiratory Reviews, vol. 10, no. 4, pp. 166–171, 2009. View at Scopus
  106. P. Desmet, K. D. Kayembe, and C. de Vroey, “The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire,” AIDS, vol. 3, no. 2, pp. 77–78, 1989. View at Scopus
  107. J. M. Tassie, L. Pepper, C. Fogg et al., “Systematic screening of cryptococcal antigenemia in HIV-positive adults in Uganda,” Journal of Acquired Immune Deficiency Syndromes, vol. 33, no. 3, pp. 411–412, 2003. View at Scopus
  108. C. A. Liechty, P. Solberg, W. Were et al., “Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda,” Tropical Medicine and International Health, vol. 12, no. 8, pp. 929–935, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. J. N. Jarvis, S. D. Lawn, M. Vogt, N. Bangani, R. Wood, and T. S. Harrison, “Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa,” Clinical Infectious Diseases, vol. 48, no. 7, pp. 856–862, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. D. B. Meya, Y. C. Manabe, B. Castelnuovo et al., “Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count ≤100 cells/μL who start HIV therapy in resource-limited settings,” Clinical Infectious Diseases, vol. 51, no. 4, pp. 448–455, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. Y. Mamoojee, S. Shakoor, R. L. Gorton et al., “Short Communication: low seroprevalence of cryptococcal antigenaemia in patients with advanced HIV infection enrolling in an antiretroviral programme in Ghana,” Tropical Medicine and International Health, vol. 16, no. 1, pp. 53–56, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. J. Oyella, D. Meya, F. Bajunirwe, and M. R. Kamya, “Prevalence and factors associated with cryptococcal antigenemia among severely immunosuppressed HIV-infected adults in Uganda: a cross-sectional study,” Journal of the International AIDS Society, vol. 15, article 15, 2012. View at Publisher · View at Google Scholar
  113. R. Micol, O. Lortholary, B. Sar et al., “Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients,” Journal of Acquired Immune Deficiency Syndromes, vol. 45, no. 5, pp. 555–559, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. P. Pongsai, K. Atamasirikul, and S. Sungkanuparph, “The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts,” Journal of Infection, vol. 60, no. 6, pp. 474–477, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. M. Feldmesser, C. Harris, S. Reichberg, S. Khan, and A. Casadevall, “Serum cryptococcal antigen in patients with AIDS,” Clinical Infectious Diseases, vol. 23, no. 4, pp. 827–830, 1996. View at Scopus
  116. S. Patel, G. Y. Shin, I. Wijewardana, et al., “The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort,” The Journal of Infection, vol. 66, no. 1, pp. 75–79, 2013. View at Publisher · View at Google Scholar
  117. R. J. Leggiadro, M. W. Kline, and W. T. Hughes, “Extrapulmonary cryptococcosis in children with acquired immunodeficiency syndrome,” Pediatric Infectious Disease Journal, vol. 10, no. 9, pp. 658–662, 1991. View at Scopus
  118. S. C. Lee, D. W. Dickson, and A. Casadevall, “Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications,” Human Pathology, vol. 27, no. 8, pp. 839–847, 1996. View at Publisher · View at Google Scholar · View at Scopus
  119. D. W. Denning, R. W. Armstrong, B. H. Lewis, and D. A. Stevens, “Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome,” American Journal of Medicine, vol. 91, no. 3, pp. 267–272, 1991. View at Publisher · View at Google Scholar · View at Scopus
  120. J. R. Graybill, J. Sobel, M. Saag et al., “Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis,” Clinical Infectious Diseases, vol. 30, no. 1, pp. 47–54, 2000. View at Publisher · View at Google Scholar · View at Scopus
  121. T. Bicanic, A. E. Brouwer, G. Meintjes et al., “Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures,” AIDS, vol. 23, no. 6, pp. 701–706, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. A. Loyse, H. Wainwright, J. N. Jarvis et al., “Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure,” AIDS, vol. 24, no. 3, pp. 405–410, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. J. R. Perfect, W. E. Dismukes, F. Dromer et al., “Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America,” Clinical Infectious Diseases, vol. 50, no. 3, pp. 291–322, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. S. Antinori, A. L. Ridolfo, E. Gianelli, M. Piazza, C. Gervasoni, and A. d'Arminio Monforte, “The role of lumbar puncture in the management of elevated intracranial pressure in patients with AIDS-associated cryptococcal meningitis,” Clinical Infectious Diseases, vol. 31, no. 5, pp. 1309–1310, 2000. View at Publisher · View at Google Scholar · View at Scopus
  125. R. D. Fessler, J. Sobel, L. Guyot et al., “Management of elevated intracranial pressure in patients with cryptococcal meningitis,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 17, no. 2, pp. 137–142, 1998. View at Scopus
  126. K. F. Macsween, T. Bicanic, A. E. Brouwer, H. Marsh, D. C. Macallan, and T. S. Harrison, “Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review,” Journal of Infection, vol. 51, no. 4, pp. e221–e224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  127. W. Manosuthi, S. Sungkanuparph, S. Chottanapund et al., “Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis,” International Journal of STD and AIDS, vol. 19, no. 4, pp. 268–271, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. M. C. Bach, P. W. Tally, and E. W. Godofsky, “Use of cerebrospinal fluid shunts in patients having acquired immunodeficiency syndrome with cryptococcal meningitis and uncontrollable intracranial hypertension,” Neurosurgery, vol. 41, no. 6, pp. 1280–1283, 1997. View at Scopus
  129. M. L. Woods II, R. MacGinley, D. P. Eisen, and A. M. Allworth, “HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection,” AIDS, vol. 12, no. 12, pp. 1491–1494, 1998. View at Publisher · View at Google Scholar · View at Scopus
  130. E. R. Jenny-Avital and M. Abadi, “Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy,” Clinical Infectious Diseases, vol. 35, no. 12, pp. e128–133, 2002. View at Scopus
  131. N. Singh, O. Lortholary, B. D. Alexander et al., “An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients,” Clinical Infectious Diseases, vol. 40, no. 12, pp. 1756–1761, 2005. View at Publisher · View at Google Scholar · View at Scopus
  132. P. R. Ingram, R. Howman, M. F. Leahy, and J. R. Dyer, “Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy,” Clinical Infectious Diseases, vol. 44, no. 12, pp. e115–e117, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. J. Cadena, G. R. Thompson III, T. T. Ho, E. Medina, D. W. Hughes, and T. F. Patterson, “Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor α blocker adalimumab in cryptococcal pneumonia,” Diagnostic Microbiology and Infectious Disease, vol. 64, no. 3, pp. 327–330, 2009. View at Publisher · View at Google Scholar · View at Scopus
  134. L. J. Haddow, R. Colebunders, G. Meintjes et al., “Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions,” The Lancet Infectious Diseases, vol. 10, no. 11, pp. 791–802, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. S. A. Shelburne, J. Darcourt, A. C. White Jr. et al., “The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy,” Clinical Infectious Diseases, vol. 40, no. 7, pp. 1049–1052, 2005. View at Publisher · View at Google Scholar · View at Scopus
  136. O. Lortholary, A. Fontanet, N. Mémain, A. Martin, K. Sitbon, and F. Dromer, “Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France,” AIDS, vol. 19, no. 10, pp. 1043–1049, 2005. View at Scopus
  137. L. J. Haddow, M. Y. Moosa, A. Mosam, P. Moodley, R. Parboosing, and P. J. Easterbrook, “Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa,” PLoS One, vol. 7, Article ID e40623, 2012.
  138. D. M. Murdoch, W. D. F. Venter, C. Feldman, and A. Van Rie, “Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study,” AIDS, vol. 22, no. 5, pp. 601–610, 2008. View at Publisher · View at Google Scholar · View at Scopus
  139. C. Michelet, C. Arvieux, C. François et al., “Opportunistic infections occurring during highly active antiretroviral treatment,” AIDS, vol. 12, no. 14, pp. 1815–1822, 1998. View at Scopus
  140. S. D. Lawn, L. G. Bekker, L. Myer, C. Orrell, and R. Wood, “Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme,” AIDS, vol. 19, no. 17, pp. 2050–2052, 2005. View at Scopus
  141. M. Müller, S. Wandel, R. Colebunders, S. Attia, H. Furrer, and M. Egger, “Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis,” The Lancet Infectious Diseases, vol. 10, no. 4, pp. 251–261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  142. S. D. Lawn and R. Wood, “Immune reconstitution inflammatory syndrome,” The Lancet Infectious Diseases, vol. 10, no. 12, pp. 833–834, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. F. J. Mateen and A. Nath, “Central nervous system-immune reconstitution inflammatory syndrome in resource-limited settings. Current burden and future needs,” AIDS, vol. 26, pp. 1851–1855, 2012. View at Publisher · View at Google Scholar
  144. D. L. Wiesner and D. R. Boulware, “Cryptococcus-Related Immune Reconstitution Inflammatory Syndrome (IRIS): pathogenesis and its Clinical Implications,” Current Fungal Infection Reports, vol. 5, no. 4, pp. 252–261, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. S. A. Shelburne III, R. J. Hamill, M. C. Rodriguez-Barradas et al., “Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy,” Medicine, vol. 81, no. 3, pp. 213–227, 2002. View at Publisher · View at Google Scholar · View at Scopus
  146. G. Breton, D. Seilhean, P. Chérin, S. Herson, and O. Benveniste, “Paradoxical intracranial cryptococcoma in a human immunodeficiency virus-infected man being treated with combination antiretroviral therapy,” American Journal of Medicine, vol. 113, no. 2, pp. 155–157, 2002. View at Publisher · View at Google Scholar · View at Scopus
  147. J. Rambeloarisoa, D. Batisse, J. B. Thiebaut et al., “Intramedullary abscess resulting from disseminated cryptococcosis despite immune restoration in a patient with AIDS,” Journal of Infection, vol. 44, no. 3, pp. 185–188, 2002. View at Publisher · View at Google Scholar · View at Scopus
  148. S. Sungkanuparph, U. Jongwutiwes, and S. Kiertiburanakul, “Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis,” Journal of Acquired Immune Deficiency Syndromes, vol. 45, no. 5, pp. 595–596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  149. T. Bicanic, G. Meintjes, K. Rebe et al., “Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 2, pp. 130–134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. S. Sungkanuparph, S. G. Filler, P. Chetchotisakd et al., “Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study,” Clinical Infectious Diseases, vol. 49, no. 6, pp. 931–934, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. D. J. Skiest, L. J. Hester, and R. D. Hardy, “Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature,” Journal of Infection, vol. 51, no. 5, pp. e289–e297, 2005. View at Publisher · View at Google Scholar · View at Scopus
  152. D. R. Boulware, D. B. Meya, T. L. Bergemann et al., “Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study,” PLoS Medicine, vol. 7, no. 12, Article ID e1000384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  153. D. R. Boulware, S. C. Bonham, D. B. Meya et al., “Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome,” Journal of Infectious Diseases, vol. 202, no. 6, pp. 962–970, 2010. View at Publisher · View at Google Scholar · View at Scopus
  154. S. K. Cinti, W. S. Armstrong, and C. A. Kauffman, “Case report. Recurrence of increased intracranial pressure with antiretroviral therapy in an AIDS patient with cryptococcal meningitis,” Mycoses, vol. 44, no. 11-12, pp. 497–501, 2001. View at Publisher · View at Google Scholar · View at Scopus
  155. M. D. King, C. A. Perlino, J. Cinnamon, and J. A. Jernigan, “Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy,” International Journal of STD and AIDS, vol. 13, no. 10, pp. 724–726, 2002. View at Publisher · View at Google Scholar · View at Scopus
  156. J. R. Boelaert, K. H. Goddeeris, L. J. Vanopdenbosch, and J. W. Casselman, “Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy,” AIDS, vol. 18, no. 8, pp. 1223–1224, 2004. View at Publisher · View at Google Scholar · View at Scopus
  157. J. York, I. Bodi, I. Reeves, P. Riordan-Eva, and P. J. Easterbrook, “Raised intracranial pressure complicating cryptococcal meningitis: immune reconstitution inflammatory syndrome or recurrent cryptococcal disease?” Journal of Infection, vol. 51, no. 2, pp. 165–171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  158. E. R. da Cunha Colombo, D. J. Mora, and M. L. Silva-Vergara, “Immune reconstitution inflammatory syndrome (IRIS) associated with Cryptococcus neoformans infection in AIDS patients,” Mycoses, vol. 54, no. 4, pp. e178–e182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  159. A. M. Cattelan, M. Trevenzoli, L. Sasset, M. Lanzafame, U. Marchioro, and F. Meneghetti, “Multiple cerebral cryptococcomas associated with immune reconstitution in HIV-1 infection,” AIDS, vol. 18, no. 2, pp. 349–351, 2004. View at Publisher · View at Google Scholar · View at Scopus
  160. A. Venkataramana, C. A. Pardo, J. C. McArthur et al., “Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients,” Neurology, vol. 67, no. 3, pp. 383–388, 2006. View at Publisher · View at Google Scholar · View at Scopus
  161. N. Khanna, R. Nüesch, C. Buitrago-Tellez, M. Battegay, and H. H. Hirsch, “Hearing loss after discontinuing secondary prophylaxis for cryptococcal meningitis: relapse or immune reconstitution?” Infection, vol. 34, no. 3, pp. 163–168, 2006. View at Publisher · View at Google Scholar · View at Scopus
  162. R. N. Khurana, M. Javaheri, and N. Rao, “Ophthalmic manifestations of immune reconstitution inflammatory syndrome associated with Cryptococcus neoformans,” Ocular Immunology and Inflammation, vol. 16, no. 4, pp. 185–190, 2008. View at Publisher · View at Google Scholar · View at Scopus
  163. A. Brunel, A. Makinson, N. Menjot de Champfleur et al., “HIV-related immune reconstitution cryptococcal meningoradiculitis: corticosteroid response,” Neurology, vol. 73, no. 20, pp. 1705–1707, 2009. View at Publisher · View at Google Scholar · View at Scopus
  164. P. Blanche, B. Gombert, C. Ginsburg et al., “HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy,” Scandinavian Journal of Infectious Diseases, vol. 30, no. 6, pp. 615–616, 1998. View at Publisher · View at Google Scholar · View at Scopus
  165. R. Manfredi, F. Pieri, S. Pileri, and F. Chiodo, “The changing face of AIDS-related opportunism: cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and literature review,” Mycopathologia, vol. 148, no. 2, pp. 73–78, 1999. View at Publisher · View at Google Scholar · View at Scopus
  166. M. Trevenzoli, A. M. Cattelan, F. Rea et al., “Mediastinitis due to cryptococcal infection: a new clinical entity in the HAART era,” Journal of Infection, vol. 45, no. 3, pp. 173–179, 2002. View at Publisher · View at Google Scholar · View at Scopus
  167. U. Legendre, M. Battegay, I. Nuttli, P. Dalquen, and R. Nüesch, “Simultaneous occurrence of 2 HIV-related immunereconstitution diseases after initiation of highly active antiretroviral therapy,” Scandinavian Journal of Infectious Diseases, vol. 33, no. 5, pp. 388–389, 2001. View at Publisher · View at Google Scholar · View at Scopus
  168. R. Lehloenya and G. Meintjes, “Dermatologic manifestations of the immune reconstitution inflammatory syndrome,” Dermatologic Clinics, vol. 24, no. 4, pp. 549–570, 2006. View at Publisher · View at Google Scholar · View at Scopus
  169. M. Tahir, S. K. Sharma, S. Sinha, and C. J. Das, “Immune reconstitution inflammatory syndrome in a patient with cryptococcal lymphadenitis as the first presentation of acquired immunodeficiency syndrome,” Journal of Postgraduate Medicine, vol. 53, no. 4, pp. 250–252, 2007. View at Scopus
  170. L. J. Haddow, F. Sahid, and M. Y. S. Moosa, “Cryptococcal breast abscess in an HIV-positive patient: arguments for reviewing the definition of immune reconstitution inflammatory syndrome,” Journal of Infection, vol. 57, no. 1, pp. 82–84, 2008. View at Publisher · View at Google Scholar · View at Scopus
  171. A. M. Sitapati, C. L. Kao, E. R. Cachay, H. Masoumi, R. S. Wallis, and W. C. Mathews, “Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab,” Clinical Infectious Diseases, vol. 50, no. 2, pp. e7–e10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. S. Antinori, A. Radice, L. Galimberti, C. Magni, M. Fasan, and C. Parravicini, “The role of cryptococcal antigen assay in diagnosis and monitoring of cryptococcal meningitis,” Journal of Clinical Microbiology, vol. 43, no. 11, pp. 5828–5829, 2005. View at Publisher · View at Google Scholar · View at Scopus
  173. E. J. McManus and J. M. Jones, “Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection,” Journal of Clinical Microbiology, vol. 21, no. 5, pp. 681–685, 1985. View at Scopus
  174. A. M. Stamm and S. S. Polt, “False-negative cryptococcal antigen test,” Journal of the American Medical Association, vol. 244, no. 12, p. 1359, 1980. View at Publisher · View at Google Scholar · View at Scopus
  175. B. P. Currie, L. F. Freundlich, M. A. Soto, and A. Casadevall, “False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis,” Journal of Clinical Microbiology, vol. 31, no. 9, pp. 2519–2522, 1993. View at Scopus
  176. R. Burton, N. Gogela, K. Rebe, M. McNally, and G. Meintjes, “Cryptococcal immune reconstitution inflammatory syndrome presenting with erosive bone lesions, arthritis and subcutaneous abscesses,” AIDS, vol. 23, no. 17, pp. 2371–2373, 2009. View at Publisher · View at Google Scholar · View at Scopus
  177. R. A. Larsen, M. A. E. Leal, and L. S. Chan, “Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial,” Annals of Internal Medicine, vol. 113, no. 3, pp. 183–187, 1990. View at Scopus
  178. J. de Gans, P. Portegies, G. Tiessens et al., “Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis,” AIDS, vol. 6, no. 2, pp. 185–190, 1992. View at Scopus
  179. R. J. Coker, M. Viviani, B. G. Gazzard et al., “Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS,” AIDS, vol. 7, no. 6, pp. 829–835, 1993. View at Scopus
  180. F. Menichetti, M. Fiorio, A. Tosti et al., “High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS,” Clinical Infectious Diseases, vol. 22, no. 5, pp. 838–840, 1996. View at Scopus
  181. A. C. A. P. Leenders, P. Reiss, P. Portegies et al., “Liposomal amphotericin B (AmBisome) compared with amphotericin and both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis,” AIDS, vol. 11, no. 12, pp. 1463–1471, 1997. View at Scopus
  182. H. Mayanja-Kizza, K. Oishi, S. Mitarai et al., “Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in ugandan patients with AIDS,” Clinical Infectious Diseases, vol. 26, no. 6, pp. 1362–1367, 1998. View at Scopus
  183. A. E. Brouwer, A. Rajanuwong, W. Chierakul et al., “Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial,” Lancet, vol. 363, no. 9423, pp. 1764–1767, 2004. View at Publisher · View at Google Scholar · View at Scopus
  184. T. Bicanic, G. Meintjes, R. Wood, et al., “Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naïve or antiretroviral-experienced patients treated with amphotericin B or fluconazole,” Clinical Infectious Diseases, vol. 45, no. 1, pp. 76–80, 2007. View at Publisher · View at Google Scholar
  185. T. Bicanic, R. Wood, G. Meintjes et al., “High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial,” Clinical Infectious Diseases, vol. 47, no. 1, pp. 123–130, 2008. View at Publisher · View at Google Scholar · View at Scopus
  186. N. Longley, C. Muzoora, K. Taseera et al., “Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda,” Clinical Infectious Diseases, vol. 47, no. 12, pp. 1556–1561, 2008. View at Publisher · View at Google Scholar · View at Scopus
  187. P. Dammert, B. Bustamante, E. Ticona et al., “Treatment of cryptococcal meningitis in Peruvian AIDS patients using amphotericin B and fluconazole,” Journal of Infection, vol. 57, no. 3, pp. 260–265, 2008. View at Publisher · View at Google Scholar · View at Scopus
  188. P. G. Pappas, P. Chetchotisakd, R. A. Larsen et al., “A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis,” Clinical Infectious Diseases, vol. 48, no. 12, pp. 1775–1783, 2009. View at Publisher · View at Google Scholar · View at Scopus
  189. R. J. Hamill, J. D. Sobel, W. El-Sadr et al., “Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety,” Clinical Infectious Diseases, vol. 51, no. 2, pp. 225–232, 2010. View at Publisher · View at Google Scholar · View at Scopus
  190. J. V. J. Lightowler, G. S. Cooke, P. Mutevedzi, R. J. Lessells, M. L. Newell, and M. Dedicoat, “Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa,” PLoS One, vol. 5, no. 1, Article ID e8630, 2010. View at Publisher · View at Google Scholar · View at Scopus
  191. D. R. Falci, L. W. Lunardi, C. G. Ramos, M. B. Bay, V. R. Aquino, and L. Z. Goldani, “Continuous infusion of amphotericin B deoxycholate in the treatment of cryptococcal meningoencephalitis: analysis of safety and fungicidal activity,” Clinical Infectious Diseases, vol. 50, no. 5, pp. e26–e29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  192. J. C. Nussbaum, A. Jackson, D. Namarika et al., “Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi,” Clinical Infectious Diseases, vol. 50, no. 3, pp. 338–344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  193. M. P. Jadhav, A. Bamba, V. M. Shinde et al., “Liposomal amphotericin B (Fungisome) for the treatment of cryptococcal meningitis in HIV/AIDS patients in India: a multicentric, randomized controlled trial,” Journal of Postgraduate Medicine, vol. 56, no. 2, pp. 71–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  194. A. Loyse, D. Wilson, G. Meintjes, et al., “Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis,” Clinical Infectious Diseases, vol. 54, no. 1, pp. 121–128, 2012. View at Publisher · View at Google Scholar
  195. C. R. Muzoora, T. Kabanda, G. Ortu, et al., “Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis,” Journal of Infection, vol. 64, no. 1, pp. 76–81, 2012. View at Publisher · View at Google Scholar
  196. J. N. Jarvis, G. Meintjes, K. Rebe, et al., “Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial,” AIDS, vol. 26, pp. 1105–1113, 2012. View at Publisher · View at Google Scholar
  197. A. T. Jackson, J. C. Nussbaum, J. Phulusa, et al., “A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis,” AIDS, vol. 26, no. 11, pp. 1363–1370, 2012. View at Publisher · View at Google Scholar
  198. M. D. Lindsley, N. Mekha, H. C. Baggett et al., “Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis,” Clinical Infectious Diseases, vol. 53, no. 4, pp. 321–325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  199. J. N. Jarvis, A. Percival, S. Bauman, et al., “Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma and urine from patients with HIV-associated cryptococcal meningitis,” Clinical Infectious Diseases, vol. 53, pp. 1019–1023, 2011. View at Publisher · View at Google Scholar
  200. R. Rajasingham, D. B. Meya, and D. R. Boulware, “Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care,” Journal of Acquired Immune Deficiency Syndromes, vol. 59, pp. e85–e91, 2012.
  201. B. J. McMullan, C. Halliday, T. C. Sorrell, et al., “Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory,” PLoS One, vol. 7, Article ID e49541, 2012.
  202. J. N. Jarvis, N. Govender, T. Chiller, et al., “Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings. A proposed algorithm for clinical implementation,” Journal of the International Association of Physicians in AIDS Care, vol. 11, pp. 374–379, 2012.
  203. R. Rajasingham and D. R. Boulware, “Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4<100 cells/mcL,” Clinical Infectious Diseases, vol. 55, pp. 1742–1744, 2012.
  204. Y. T. Huang, C. C. Hung, C. H. Liao, H. Y. Sun, S. C. Chang, and Y. C. Chen, “Detection of circulating galactomannan in serum samples for diagnosis of Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus,” Journal of Clinical Microbiology, vol. 45, no. 9, pp. 2858–2862, 2007. View at Publisher · View at Google Scholar · View at Scopus
  205. M. O. Xavier, A. C. Pasqualotto, I. C. E. Cardoso, and L. C. Severo, “Cross-reactivity of Paracoccidioides brasiliensis, Histoplasma capsulatum, and Cryptococcus species in the commercial platelia Aspergillus enzyme immunoassay,” Clinical and Vaccine Immunology, vol. 16, no. 1, pp. 132–133, 2009. View at Publisher · View at Google Scholar · View at Scopus
  206. J. R. Perfect, “The triple threat of cryptococcosis: it’s the body site, the strain, and/or the host,” mBio, vol. 3, no. 4, pp. e00165–e00112, 2012. View at Publisher · View at Google Scholar
  207. T. A. Bicanic, C. Muzoora, A. E. Brouwer et al., “Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients,” Clinical Infectious Diseases, vol. 49, no. 5, pp. 702–709, 2009. View at Publisher · View at Google Scholar · View at Scopus
  208. Antiretroviral Therapy Cohort Collaboration, “Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal,” Clinical Infectious Diseases, vol. 48, no. 8, pp. 1138–1151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  209. O. Lortholary, G. Poizat, V. Zeller, et al., “Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy,” AIDS, vol. 20, pp. 2183–2191, 2006. View at Publisher · View at Google Scholar
  210. U. Jongwutiwes, S. Kiertiburanakul, and S. Sungkanuparph, “Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection,” Current HIV Research, vol. 5, no. 3, pp. 355–360, 2007. View at Publisher · View at Google Scholar · View at Scopus
  211. W. G. Powderly, M. S. Saag, G. A. Cloud et al., “A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome,” The New England Journal of Medicine, vol. 326, no. 12, pp. 793–798, 1992. View at Scopus
  212. S. A. Bozzette, R. A. Larsen, J. Chiu et al., “A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome,” The New England Journal of Medicine, vol. 324, no. 9, pp. 580–584, 1991. View at Scopus
  213. M. S. Saag, G. A. Cloud, J. R. Graybill, et al., “A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis,” Clinical Infectious Diseases, vol. 28, no. 2, pp. 291–296, 1999. View at Scopus
  214. WHO, Rapid Advice. Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children, WHO Press, Geneva, Switzerland, 2011, http://whqlibidoc.who.int/publications/2011/9789241502979_eng.pdf.
  215. R. Rajasingham, M. A. Rolfes, K. E. Birkenkamp, D. B. Meya, and D. R. Boulware, “Cryptococcal meningitis treatment strategies in resource-limited settings. A cost-effectiveness analysis,” PLoS Medicine, vol. 9, Article ID e1001316, 2012.
  216. D. W. Bates, L. Su, D. T. Yu et al., “Mortality and costs of acute renal failure associated with amphotericin B therapy,” Clinical Infectious Diseases, vol. 32, no. 5, pp. 686–693, 2001. View at Publisher · View at Google Scholar · View at Scopus
  217. M. Nelson, H. Manji, and E. Wilkins, “Central nervous system opportunistic infections. British HIV association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals,” HIV Medicine, vol. 12, supplement 2, pp. 8–24, 2011.
  218. T. Bicanic, D. Ogden, I. Whitney, A. Loyse, and J. Jarvis, “British HIV association opportunistic infection guidelines: in defence of amphotericin B deoxycholate,” HIV Medicine, vol. 13, pp. 636–637, 2012.
  219. A. R. Zolopa, J. Andersen, W. Powderly et al., “Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial,” PLoS One, vol. 4, no. 5, Article ID e5575, 2009. View at Publisher · View at Google Scholar · View at Scopus
  220. A. T. Makadzange, C. E. Ndhlovu, K. Takarinda et al., “Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa,” Clinical Infectious Diseases, vol. 50, no. 11, pp. 1532–1538, 2010. View at Publisher · View at Google Scholar · View at Scopus
  221. P. M. Grant, L. Komarow, J. Andersen et al., “Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection,” PloS One, vol. 5, no. 7, Article ID e11416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  222. K. McCarthy and G. Meintjes, “Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients,” Southern African Journal of HIV Medicine, vol. 28, no. 3, pp. 25–35, 2007.
  223. E. Martínez, M. A. García-Viejo, M. A. Marcos et al., “Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy,” AIDS, vol. 14, no. 16, pp. 2615–2617, 2000. View at Publisher · View at Google Scholar · View at Scopus
  224. F. Rollot, P. Bossi, R. Tubiana et al., “Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy,” AIDS, vol. 15, no. 11, pp. 1448–1449, 2001. View at Publisher · View at Google Scholar · View at Scopus
  225. N. C. Nwokolo, M. Fisher, B. G. Gazzard, and M. R. Nelson, “Cessation of secondary prophylaxis in patients with cryptococcosis,” AIDS, vol. 15, no. 11, pp. 1438–1439, 2001. View at Publisher · View at Google Scholar · View at Scopus
  226. J. A. Aberg, R. W. Price, D. M. Heeren, and B. Bredt, “A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy,” Journal of Infectious Diseases, vol. 185, no. 8, pp. 1179–1182, 2002. View at Publisher · View at Google Scholar · View at Scopus
  227. W. H. Sheng, C. C. Hung, M. Y. Chen, S. M. Hsieh, and S. C. Chang, “Successful discontinuation of fluconazole as secondary prophylaxis for cryptococcosis in AIDS patients responding to highly active antiretroviral therapy,” International Journal of STD and AIDS, vol. 13, no. 10, pp. 702–705, 2002. View at Publisher · View at Google Scholar · View at Scopus
  228. O. Kirk, P. Reiss, C. Uberti-Foppa et al., “Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy,” Annals of Internal Medicine, vol. 137, no. 4, pp. 239–250, 2002. View at Scopus
  229. C. Mussini, P. Pezzotti, J. M. Miró et al., “Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study,” Clinical Infectious Diseases, vol. 38, no. 4, pp. 565–571, 2004. View at Publisher · View at Google Scholar · View at Scopus
  230. H. Y. Sun, M. Y. Chen, C. F. Hsiao, S. M. Hsieh, C. C. Hung, and S. C. Chang, “Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated with highly active anti-retroviral therapy,” Clinical Microbiology and Infection, vol. 12, no. 4, pp. 381–388, 2006. View at Publisher · View at Google Scholar · View at Scopus
  231. A. Vibhagool, S. Sungkanuparph, P. Mootsikapun et al., “Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study,” Clinical Infectious Diseases, vol. 36, no. 10, pp. 1329–1331, 2003. View at Publisher · View at Google Scholar · View at Scopus
  232. S. Antinori, “Molluscum or a mimic? Add Penicillium marneffei!,” American Journal of Medicine, vol. 120, no. 11, pp. e19–e20, 2007. View at Publisher · View at Google Scholar · View at Scopus
  233. W. G. Powderly, D. M. Finkelstein, J. Feinberg et al., “A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection,” The New England Journal of Medicine, vol. 332, no. 11, pp. 700–705, 1995. View at Publisher · View at Google Scholar · View at Scopus
  234. V. J. Quagliarello, C. Viscoli, and R. I. Horwitz, “Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients,” Lancet, vol. 345, no. 8949, pp. 548–552, 1995. View at Publisher · View at Google Scholar · View at Scopus
  235. J. A. Newton, S. A. Tasker, W. D. Bone et al., “Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact on the incidence of disseminated cryptococcal infection,” AIDS, vol. 9, no. 11, pp. 1286–1287, 1995. View at Scopus
  236. D. V. Havlir, M. P. Dube, J. A. McCutchan, et al., “Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS,” Clinical Infectious Diseases, vol. 27, no. 6, pp. 1369–1375, 1998.
  237. P. Chetchotisakd, S. Sungkanuparph, B. Thinkhamrop, P. Mootsikapun, and P. Boonyaprawit, “A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency,” HIV Medicine, vol. 5, no. 3, pp. 140–143, 2004. View at Publisher · View at Google Scholar · View at Scopus
  238. P. T. Cantey, D. S. Stephens, and D. Rimland, “Prevention of cryptococcosis in HIV-infected patients with limited access to highly active antiretroviral therapy: evidence for primary azole prophylaxis,” HIV Medicine, vol. 6, no. 4, pp. 253–259, 2005. View at Publisher · View at Google Scholar · View at Scopus
  239. R. Micol, A. Tajahmady, O. Lortholary et al., “Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia,” PLoS One, vol. 5, no. 11, Article ID e13856, 2010. View at Publisher · View at Google Scholar · View at Scopus
  240. R. Parkes-Ratanshi, K. Wakeham, J. Levin, et al., “Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised placebo-controlled trial,” Lancet Infectious Diseases, vol. 11, pp. 933–941, 2011. View at Publisher · View at Google Scholar